All In MedTech

FDA Clearance Tracker · P160049-S015

Stellarex 0.035OTW Drug-coated Angioplasty Balloon

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 25, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 25, 2022

Approved

Time to decision

177 days

Received Sep 29, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160049-S015
Device name
Stellarex 0.035OTW Drug-coated Angioplasty Balloon
Applicant location
Fremont, CA
Received
Sep 29, 2021
Decided
Mar 25, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160049

Device type

Device class
Class III

Every decision under product code ONU

FDA's approval statement

As written in FDA's record.

Approval for The Stellarex 0.035 inch OTW Drug-coated Angioplasty Balloon. The Stellarex 0.035 inch OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions up to 180 mm in length in superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.

Source documents

Other decisions for The Spectranetics Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.